Ocular Therapeutix (OCUL) Other Non Operating Income (2013 - 2026)
Ocular Therapeutix (OCUL) recorded quarterly Other Non Operating Income of $1.8 million in Q1 2026, up 4.99% quarter-over-quarter from $1.7 million in Q4 2025, and up 402.31% on a YoY basis from $364714.8 in Q1 2025.
Ocular Therapeutix (OCUL) Other Non Operating Income (2013 - 2026) Analysis & Trends
Ocular Therapeutix's Other Non Operating Income history runs 13 years deep, the most recent figure standing at $1.8 million for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 402.31% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $2.5 million (down 45.82% YoY), while the FY2025 annual figure was $29000.0, up 100.1% from the prior year.
- Other Non Operating Income was $1.8 million for Q1 2026 at Ocular Therapeutix, up from $1.7 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $14.2 million in Q3 2023 to a low of -$28.0 million in Q1 2024.
- Historically, Other Non Operating Income has averaged -$1.1 million across 5 years, with a median of -$1000.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Other Non Operating Income surged 1418900.0% in 2023, then tumbled 2794900.0% in 2024.
- A 5-year view of Other Non Operating Income shows it stood at $1000.0 in 2022, then tumbled by 1419200.0% to -$14.2 million in 2023, then soared by 153.65% to $7.6 million in 2024, then sank by 77.08% to $1.7 million in 2025, then gained by 4.99% to $1.8 million in 2026.
- The last three Other Non Operating Income figures came in at $1.8 million (Q1 2026), $1.7 million (Q4 2025), and -$938000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ocular Therapeutix | 2.12 Bn | 2.12 Bn | 9.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.83 Mn |
| Dec 31, 2025 | 1.75 Mn |
| Sep 30, 2025 | -938,000.00 |
| Jun 30, 2025 | -172,000.00 |
| Mar 31, 2025 | -606,000.00 |
| Sep 30, 2024 | 7.61 Mn |
| Jun 30, 2024 | -2.45 Mn |
| Mar 31, 2024 | -27.95 Mn |
| Dec 31, 2023 | -14.19 Mn |
| Sep 30, 2023 | 14.19 Mn |
| Jun 30, 2023 | 1.13 Mn |
| Mar 31, 2023 | -1,000.00 |
| Sep 30, 2022 | 1,000.00 |
| Jun 30, 2022 | 2.77 Mn |
| Mar 31, 2022 | -2,000.00 |
| Dec 31, 2021 | -62.25 Mn |
| Sep 30, 2021 | 23.84 Mn |
| Jun 30, 2021 | 13.40 Mn |
| Mar 31, 2021 | 25.02 Mn |
| Dec 31, 2020 | -69.55 Mn |